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Hyperventilation  syndrome  is  an  acute  complication  sometimes  encountered  in  dentistry  and  is  generally
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were  dramatically  improved  or  prevented  by  intravenous  administration  of  a beta-adrenergic  blocker.
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. Introduction
Hyperventilation syndrome (HVS), the various symptoms of
hich include hyperventilation, carpal-pedal spasm, tachycardia,
umbness of the extremities, unconsciousness, etc. [1,2] is an acute
omplication sometimes encountered in dentistry [3,4]. Benzodi-
zepines are generally used for treatment and prevention of HVS
3]. However, intravenous administration of benzodiazepines for
reatment of HVS sometimes induces hypoxemia and even death
5,6]. We  report three cases with HVS that were dramatically
mproved or prevented by an intravenous beta-adrenergic blocker.
. Case reports
.1.  Case 1
A  28-year-old, 53-kg healthy woman came to our oral and max-
llofacial surgery outpatient clinic for removal of several teeth for
rthodontics treatment. Her medical history was  unremarkable,
nd she had no known allergies. However, she needed general
ental care because she had experienced a hyperventilation attack
hree times during the past two years.
Although she seemed to be nervous in the dental chair, her
lood pressure was 110/65 mmHg, her pulse rate 70 beats/min, and
er respirations 16 breaths/min. To prevent HVS she was admin-
stered midazolam 3.5 mg  and pentazocine 15 mg  intravenously,
hich produced the desired level of conscious sedation. The tooth
as extracted after inﬁltration anesthesia (2% lidocaine contain-
∗ Corresponding author. Tel.: +81 88 633 7367; fax: +81 88 633 7368.
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oi:10.1016/S1348-8643(11)00006-1ing 1:240,000 epinephrine, 5.0 ml). The procedure was  ﬁnished
safely in 35 min. On recovery, 30 min after the tooth extraction,
she suddenly began to hyperventilate and complained of pain in
the area of the tooth extraction. Her rate of respiration increased
to approximately 40 breaths/min and her heart rate increased to
140 beats/min. The arterial pH and PaCO2 measured in blood from
a radial artery were 7.61 and 21 mmHg, respectively. We diagnosed
her condition as HVS caused by the pain from the tooth extrac-
tion. Immediately after we  administered pentazocine 15 mg  and
midazolam 1.5 mg  intravenously, her respiration was depressed
and then stopped. SpO2 deteriorated to 58%. We ventilated her
using an Ambu Bag and administered ﬂumazenil 0.1 mg  twice
because we suspected that her respiratory depression was  caused
by midazolam. After the administration, she awoke and stated that
she had no pain. However, within a few minutes she suddenly
began to hyperventilate again and lost consciousness. Rebreathing
from a paper bag was performed but had no effect. After hyper-
ventilating for a few minutes, she suddenly ceased spontaneous
respiration. We  again ventilated her using an Ambu Bag. After that,
hyperventilation followed by apnea was repeated every few min-
utes. Tachycardia above 130 beats/min persisted. As soon as we
administered the beta-adrenergic blocker, propranolol hydrochlo-
ride 1.5 mg  intravenously, the heart rate fell to 60–70 beats/min
and the hyperventilation soon stopped. She did not hyperventilate
again during this appointment.
At  the second appointment, analgesics and a beta-blocker were
selected to prevent HVS because the HVS at the ﬁrst appointment
was caused by the postoperative pain and the beta-adrenergic
blocker was found to be effective on that occasion. Loxoprofen
sodium 60 mg  per os and buprenorphine 0.2 mg intravenously were
administered before the tooth extractions. Although propranolol
hydrochloride 1 mg  was  administered intravenously to prevent
evier Ltd. All rights reserved.
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VS, the heart rate and blood pressure did not change. After admin-
stering inﬁltration anesthesia (2% lidocaine containing 1:240,000
pinephrine, 4.8 ml), the tooth was extracted. She complained of
reathlessness twice during the procedure. Although her respira-
ory rate was temporarily increased to 28 breaths/min, her heart
ate was about 60 beats/min and she did not experience HVS.
.2. Case 2
A  60-year-old, healthy woman was referred to our outpatient
linic for removal of a third molar, because she was  anxious in
egard to receiving anesthesia.
The patient was scheduled for local anesthesia under moni-
oring as an outpatient. She seemed to be very nervous before
reatment. Her blood pressure was 138/82 mmHg, her pulse
00 beats/min, and her respirations 18 breaths/min. Although the
ooth extraction was started after inﬁltration anesthesia (2% lido-
aine containing 1:240,000 epinephrine, 1.8 ml), she complained
f pain. When additional inﬁltration anesthesia was  performed,
er pulse rate suddenly increased to 160 beats/min and her res-
iration rate increased to approximately 40–50 breaths/min. She
omplained of breathlessness and numbness of the extremities.
arpopedal spasm was also observed. We  diagnosed her condition
s HVS. We  administered a beta-adrenergic blocker, propranolol
ydrochloride 1.0 mg  intravenously. As soon as her heart rate fell to
0 beats/min, the hyperventilation stopped. After about 5 min, the
umbness of the extremities also disappeared. She did not begin to
yperventilate again during the subsequent treatment.
.3. Case 3
A  41-year-old woman came to our oral and maxillofacial surgery
or the removal of two third molars. She had experienced hyper-
entilation attacks four times over the past seven years. All of
er hyperventilation attacks occurred just after inﬁltration anes-
hesia in preparation for dental procedures. In all of these cases,
he felt palpitations immediately after inﬁltration anesthesia, and
hen breathlessness and numbness of the extremities. However,
he never lost consciousness. These symptoms disappeared after
bout 5 h follow-up.
We selected a beta-adrenergic blocker to prevent HVS because
he initial symptom of her HVS was palpitation. A beta-adrenergic
locker, propranolol hydrochloride 1.0 mg,  was administered intra-
enously before the tooth extractions. Her blood pressure was
10/60 mmHg  and her pulse 70 beats/min. Although local anesthet-
cs (2% lidocaine containing 1:240,000 epinephrine, 5.1 ml) were
njected into the alveolar gingiva, her pulse rate never increased.
he never complained of HVS symptoms including palpitation,
reathlessness, or numbness of the extremities during the proce-
ure.
. Discussion
Post-hyperventilation hypoxemia may  occur in patients with
VS during posthyperventilation stage, because posthyperven-
ilation breathing from hypocapnia to normocapnia is always
ccompanied by hypoventilation including apnea. Although hypox-
mia is thought to be the major respiratory stimulus by chemical
entilatory responses, the hypoxemic ventilatory response is atten-
ated under sleeping or unconscious conditions [7]. It has been
eported that a patient with HVS died after the administration of
iazepam to treat a hyperventilation attack [6]. Hypoxemia seems
o become more severe when the patient with HVS is sedated with
enzodiazepines, because the depression of consciousness level by
enzodiazepines attenuates compensation due to behavioral res-
iratory control. As a result, oxygen inhalation will be necessary
o prevent severe hypoxemia following the administration of ben-
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zodiazepines.  Taken together, a beta-adrenergic blocker that does
not depress the central nervous system may  be effective for the
treatment of HVS.
Anxiety,  one of the main causes of HVS in dentistry, is associ-
ated with increased sympatho-adrenal activity. The mean urinary
excretion of adrenaline in patients with HVS has been reported to be
three-fold higher than that in patients who do not experience HVS
[8]. In other studies, intravenous infusions of norepinephrine and
isoproterenol caused signiﬁcant increases in minute volume and
decreases in end-tidal PCO2 which were blocked by the administra-
tion of a beta-adrenergic receptor blocker [9,10]. Many symptoms
of HVS may  be interpreted on the basis of the increased sympathoa-
drenal tone, especially beta-adrenergic activity. Benzodiazepines
are generally used for prevention of HVS [3]. However, cases 1 and
3 could be managed using a beta-adrenergic blocker irrespective
of psychosedation, suggesting that blockade of the sympathoad-
renal tone, especially blockade of tachycardia, by a beta-adrenergic
blocker may  help to prevent HVS. We  think that benzodiazepine
may be effective for the prevention of HVS in cases with severe
anxiety and that beta-adrenergic blocker may  be effective for HVS
patients who  are extremely sensitive to increase of sympathoad-
renal tone, such as elevation of pulse rate and blood pressure.
The  effects of beta-adrenergic blocker occur via the cardio-
vascular system. In all of the present cases, the beta-adrenergic
blocker realized the expected decrease in heart rate without caus-
ing a depression in blood pressure. However, these drugs should be
administered with careful and frequent monitoring of blood pres-
sure, electrocardiography, and cardiac function. Furthermore, it is
necessary to be careful about  adrenergic–mediated hypertension
when nonselective beta-adrenergic blockers and epinephrine are
used together.
Hypocapnia causes a 130–140% increase in airway resistance
in normals and a 255% increase in airway resistance in asthmatics
[8]. Furthermore, many asthmatics hyperventilate. The administra-
tion of nonselective beta-adrenergic blockers for patients with HVS
may  be undesirable because it runs the risk of inducing an asth-
matic attack. Thus, a beta-1 selective blocker should be selected for
treatment and prevention of HVS in asthmatics.
In summary, this article suggests that beta-adrenergic blockers
may be effective for the treatment and prevention of HVS. However,
because we  considered only three patients, further clinical studies
will be needed to conﬁrm this.
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